07:17:16 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2025-02-02 Bokslutskommuniké 2024
2024-11-07 Kvartalsrapport 2024-Q3
2024-08-26 Kvartalsrapport 2024-Q2
2024-05-15 Halvårsutdelning CONTX 0.15026
2024-05-14 Årsstämma 2024
2024-05-08 Kvartalsrapport 2024-Q1
2024-02-15 Bokslutskommuniké 2023
2023-11-02 Halvårsutdelning CONTX 0.15741
2023-10-26 Kvartalsrapport 2023-Q3
2023-08-24 Kvartalsrapport 2023-Q2
2023-05-08 Halvårsutdelning CONTX 0.15741
2023-05-03 Årsstämma 2023
2023-04-27 Kvartalsrapport 2023-Q1
2023-02-16 Bokslutskommuniké 2022
2022-10-20 Kvartalsrapport 2022-Q3
2022-08-11 Kvartalsrapport 2022-Q2
2022-05-05 Ordinarie utdelning CONTX 0.00 NOK
2022-05-04 Årsstämma 2022
2022-04-21 Kvartalsrapport 2022-Q1
2022-02-17 Bokslutskommuniké 2021
2021-12-10 Extra Bolagsstämma 2021
2021-10-21 Kvartalsrapport 2021-Q3
2021-08-12 Kvartalsrapport 2021-Q2
2021-05-06 Ordinarie utdelning CONTX 0.00 NOK
2021-05-05 Årsstämma 2021
2021-04-22 Kvartalsrapport 2021-Q1
2021-02-18 Bokslutskommuniké 2020
2020-10-22 Kvartalsrapport 2020-Q3
2020-08-19 Split CONTX 1:10
2020-08-13 Kvartalsrapport 2020-Q2
2020-08-05 Extra Bolagsstämma 2020
2020-05-07 Ordinarie utdelning CONTX 0.00 NOK
2020-05-06 Årsstämma 2020
2020-04-23 Kvartalsrapport 2020-Q1
2020-02-20 Bokslutskommuniké 2019
2019-10-24 Kvartalsrapport 2019-Q3
2019-08-15 Kvartalsrapport 2019-Q2
2019-05-09 Ordinarie utdelning CONTX 0.00 NOK
2019-05-08 Årsstämma 2019
2019-04-25 Kvartalsrapport 2019-Q1
2019-02-21 Bokslutskommuniké 2018
2018-10-25 Kvartalsrapport 2018-Q3
2018-08-16 Kvartalsrapport 2018-Q2
2018-05-11 Ordinarie utdelning CONTX 0.00 NOK
2018-05-09 Årsstämma 2018
2018-04-26 Kvartalsrapport 2018-Q1
2018-02-22 Bokslutskommuniké 2017
2017-10-26 Kvartalsrapport 2017-Q3
2017-08-17 Kvartalsrapport 2017-Q2
2017-05-11 Ordinarie utdelning CONTX 0.00 NOK
2017-05-10 Årsstämma 2017
2017-04-27 Kvartalsrapport 2017-Q1
2017-02-23 Bokslutskommuniké 2016
2016-10-27 Kvartalsrapport 2016-Q3
2016-08-18 Kvartalsrapport 2016-Q2
2016-04-21 Kvartalsrapport 2016-Q1
2016-04-21 Ordinarie utdelning CONTX 0.00 NOK
2016-04-20 Årsstämma 2016
2016-02-18 Bokslutskommuniké 2015
2015-10-22 Kvartalsrapport 2015-Q3
2015-08-20 Kvartalsrapport 2015-Q2
2015-04-23 Ordinarie utdelning CONTX 0.00 NOK
2015-04-23 Kvartalsrapport 2015-Q1
2015-04-22 Årsstämma 2015
2015-02-19 Bokslutskommuniké 2014
2014-10-23 Kvartalsrapport 2014-Q3
2014-08-21 Kvartalsrapport 2014-Q2
2014-05-12 15-7 2014
2014-04-24 Ordinarie utdelning CONTX 0.00 NOK
2014-04-24 Kvartalsrapport 2014-Q1
2014-04-23 Årsstämma 2014
2014-02-20 Bokslutskommuniké 2013
2013-10-24 Kvartalsrapport 2013-Q3
2013-08-22 Kvartalsrapport 2013-Q2
2013-06-13 Ordinarie utdelning CONTX 0.00 NOK
2013-06-12 Årsstämma 2013
2013-04-25 Kvartalsrapport 2013-Q1
2013-02-21 Bokslutskommuniké 2012
2012-10-25 Kvartalsrapport 2012-Q3
2012-08-23 Kvartalsrapport 2012-Q2
2012-06-14 Ordinarie utdelning CONTX 0.00 NOK
2012-06-13 Årsstämma 2012
2012-04-26 Kvartalsrapport 2012-Q1
2012-02-23 Bokslutskommuniké 2011
2011-10-27 Kvartalsrapport 2011-Q3
2011-08-25 Kvartalsrapport 2011-Q2
2011-06-10 Ordinarie utdelning CONTX 0.00 NOK
2011-06-09 Årsstämma 2011
2011-04-28 Kvartalsrapport 2011-Q1
2011-02-17 Bokslutskommuniké 2010
2010-10-21 Kvartalsrapport 2010-Q3
2010-08-19 Kvartalsrapport 2010-Q2
2010-06-04 Ordinarie utdelning CONTX 0.00 NOK
2010-06-03 Årsstämma 2010
2010-04-21 Kvartalsrapport 2010-Q1
2010-02-18 Bokslutskommuniké 2009
2009-10-22 Kvartalsrapport 2009-Q3
2009-08-20 Kvartalsrapport 2009-Q2
2009-04-23 Kvartalsrapport 2009-Q1
2008-06-06 Ordinarie utdelning CONTX 1.50 NOK

Beskrivning

LandSverige
ListaOB Match
SektorHälsovård
IndustriMedicinteknik
ContextVision är ett medicinteknologiskt bolag. Bolaget specialiserar sig inom bildanalys och artificiell intelligens. Bland bolagets produkter återfinns avancerade bildförbättringsprogram för ultraljud, MRI, röntgen och mammografi. Programvarorna används idag av sjukhus och forskningsinstitut på global nivå. Bolaget grundades 1983 och har sitt huvudkontor i Stockholm.
2021-11-15 14:55:35

The shareholders of ContextVision AB, corporate registration number 556377-8900, are hereby invited to attend an extraordinary general meeting on the 10 December, 2021 at 10 a.m CET at ContextVision AB's office, Klara Norra Kyrkogata 31, 111 22, Stockholm.

Right to participate and notification

Shareholders who wish to participate in the annual general meeting with the right to vote shall

  • be entered in the share register kept by Euroclear Sweden AB as of Thursday, 2 December 2021, and
  • give notice of attendance to the company in writing at the latest on Friday, 3 December 2021.

The notice of attendance can be given by e-mail to finance@contextvision.se or by post to Klara Norra Kyrkogata 31, 111 22 Stockholm.

Nominee registered shares

A shareholder who has its shares registered with a nominee must, in order to be entitled to participate in the general meeting, have the shares registered in its own name through the nominee, so that the shareholder is registered in the share register kept by Euroclear Sweden AB on the record date of Thursday, 2 December 2021. Such registration may be temporary (so-called voting rights registration). Shareholders who wish to register the shares in their own name must, in accordance with the respective nominee's routines, request that the nominee make such voting rights registration. Registration of voting rights that have been requested by shareholders at such a time that the registration has been made by the relevant nominee no later than Monday, 6 December 2021 will be taken into account when preparing the register of shareholders.

Particular for shareholders registered at Norska Verdipapirsentralen (VPS)

  • Shareholders registered at Norska Verdipapirsentralen (VPS) who are not registered at Euroclear Sweden AB, Sweden, and wish to be entitled to vote at the extraordinary general meeting must give notice of attendance to DNB Bank ASA at the latest on 29 November 2021, at 12:00 (noon) local time. The notice of attendance is made on a specific application form which will be sent by post to the shareholders and also be available on the company’s website. The notice of attendance shall be sent to DNB Bank ASA, Verdipapirservice, PB 1600 Sentrum, N-0021 Oslo, or by e-mail to vote@dnb.no.
  • DNB Bank ASA will temporarily record the shares at Euroclear Sweden AB in the name of the shareholder. Shareholders recorded at VPS must also, as described above, give notice of attendance to the company in order to obtain the right to vote at the extraordinary general meeting.

Proposed agenda:

  1. Election of a chairman of the meeting.
  2. Preparation and approval of the voting list.
  3. Election of one person to approve the minutes of the meeting.
  4. Determination of whether the meeting was duly convened.
  5. Approval of the agenda.
  6. Resolution on dividend of all shares in the Company's subsidiary containing the line of business Digital Pathology.
  7. Closing of the meeting.


The board of directors' proposal for a resolution on dividend of all shares in the Company's subsidiary containing the line of business Digital Pathology. (item 6)
The board of directors proposes that the extraordinary general meeting resolves that all shares in the company's wholly-owned Swedish subsidiary Inify Laboratories AB (under name change from Goldcup 100833 AB), reg.no 559345-4431, ("Inify Laboratories") containing ContextVision AB's current business segment Digital Pathology to be distributed to the shareholders in ContextVision AB, whereby one (1) share in ContextVision AB shall entitle to receipt of one (1) share in Inify Laboratories. The board of directors further proposes that the extraordinary general meeting authorises the board of directors to determine the record date for the right to receive the dividend.

The distribution of the shares in Inify Laboratories is expected to be made in accordance with the so-called Lex Asea rules. Lex Asea is a Swedish tax regulation. The provision implies, in brief, that the shares in a subsidiary under certain circumstances can be distributed without triggering any immediate taxation of the dividend for Swedish resident shareholders (instead, the tax basis for the shares in the parent company is allocated between the shares in the parent company and the received shares in the subsidiary).

Before the distribution is carried out, tangible assets, intangible assets, intellectual property rights and cash corresponding to an aggregate value of SEK 31,253,000 will be transferred from ContextVision AB to Inify Laboratories (the "Carve Out").

The value of the distribution of the shares in Inify Laboratories is determined based on the book value at the time of the distribution of the shares to ContextVision AB's shareholders by application of relevant accounting rules. ContextVision AB estimates the book value at the time of the distribution to be SEK 31,753,000, which hence is the total value that is proposed to be distributed to the shareholders.

According to the company's latest approved balance sheet, the company has SEK 30,955,000 in unrestricted equity. No previous resolution on value transfer has been made since the balance sheet was adopted and no alterations in the restricted equity have resulted in the available capital for dividends, pursuant to Chapter 17, Section 3, first paragraph of the Swedish Companies Act, to be limited. In connection with the Carve Out, the portion of ContextVision AB's fund for development costs relating to Digital Pathology, amounting to SEK 13,293,717, will be dissolved, implying that ContextVision AB's unrestricted equity will increase with the same amount. The board of directors therefore assesses that the proposed dividend falls within the available unrestricted equity. Following the distribution of ContextVision AB's shares in Inify Laboratories in accordance with the board of directors' proposal it is assessed, pursuant to Chapter 17, Section 3, first paragraph of the Swedish Companies Act, that the remaining available capital will amount to approximately SEK 12,495,717.

Following the execution of the dividend, a reverse stock split of the shares in Inify Laboratories will be carried out, whereby ten (10) shares in Inify Laboratories will be combined into one (1) share. The reverse stock split is conditional upon that one of Inify Laboratories' large shareholders will agree to contribute with shares to the shareholders whose holding of shares is not evenly divisible by ten (10), as well as to round down its remaining holding of shares in Inify Laboratories to the nearest number that is evenly divisible by ten (10). The reverse stock split is taking place in order to achieve an appropriate number of shares in Inify Laboratories. Following the reverse stock split the number of shares in Inify Laboratories will amount to 7,736,750.

The board of directors proposes that the board of directors, the CEO or any person they appoint shall have the right to make minor adjustments of the resolution above that are deemed necessary in conjunction with the registration with the Swedish Companies Registration Office and/or Euroclear Sweden AB and/or VPS, and otherwise to take necessary measures to implement the resolution.

In order for the resolution by the extraordinary general meeting in accordance with the board of directors’ proposal under item 6 above to be valid, shareholders representing more than fifty per cent of the votes cast must be in favour of the proposal or, in case of parity of votes, the chairman of the meeting being in favour of the proposal.

The number of shares and votes
The number of outstanding votes in the company at the time of this notice amounts to a total of 77,367,500 divided into a total of 77,367,500 shares. The company holds no own shares.

Personal data
For information on how your personal data is processed, please see https://www.euroclear.com/dam/ESw/Legal/Privacy-notice-bolagsstammor-engelska.pdf

Available documents
The board of director's complete proposal under item 6 and the company’s Annual Report and the Auditor’s Report for the financial year 2020 are available at ContextVision AB, Klara Norra Kyrkogata 31, Stockholm. The board of director's statements pursuant to Chapter 18, Sections 4 and 6 of the Swedish Companies Act and a statement from the auditor pursuant to Chapter 18, Section 6 of the Swedish Companies Act will be available at ContextVision AB, Klara Norra Kyrkogata 31, Stockholm at the latest on 26 November 2021. Copies of the documents will be sent to shareholders upon request and will be available at the extraordinary general meeting


Shareholders' right to request information
At the extraordinary general meeting, if the board of directors determines that it can be disclosed without material damage to the company, shareholders have a right to obtain information on conditions that may affect the assessment of an agenda item and conditions that may affect the assessment of the company’s financial situation.

Linköping in November 2021
CONTEXTVISION AB (PUBL)
The Board of Directors


This information is considered to be inside information pursuant to the EU Market Abuse Regulation and is subject to the disclosure requirements pursuant to section 5-12 the Norwegian Securities Trading Act.